mash and semaglutide Improves Histology in MASH: Phase 3 ESSENCE Trial ESSENCE: Semaglutide in Patients with

Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, et al

As eligibility expands and more countries adopt these therapies, access and affordability will determine global health outcomes

For example, semaglutide achieved NASH resolution in up to 59% of patients at the 0.4 mg dosage, compared to only 17% in the placebo group

High doses may lead to the K-hole phenomenon, characterized by extreme dissociation without loss of consciousness (Malhotra et al., 1996)

For more detailed discussions, you can listen to episodes of the RELATED QUESTIONS

If nausea was your main complaint with semaglutide, this switch is worth discussing with your doctor